VIR catalyst calendar

Vir Biotechnology, Inc.

Upcoming catalysts
7
Cash runway
12 months
Cash & investments
$529M
Phase 3 programs
4

Vir Biotechnology, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on October 16, 2026, a projected date rather than a confirmed one. There are 7 upcoming events on record.

Cash runway is approximately 12 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 15 concluded trials, 80% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 16, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2026 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Trial Milestone Phase 2
December 15, 2026 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Trial Milestone Phase 3
December 31, 2026 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Trial Milestone Phase 3
April 15, 2028 To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Trial Milestone Phase 1/Phase 2
August 15, 2029 Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
November 15, 2031 SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. Trial Milestone Phase 2

Track VIR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open VIR in the tracker

Recent history

DateEventTypePhase
October 14, 2026 8-K filed: Other event Filing —
October 8, 2026 8-K filed: Other event Filing —
October 1, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 24, 2026 8-K filed: Leadership change Corporate —
June 10, 2026 8-K filed: Leadership change Corporate —
May 28, 2026 8-K filed: Leadership change Corporate —
May 6, 2026 Quarterly results filed (8-K) Earnings —
April 10, 2026 8-K filed: Leadership change Corporate —
March 16, 2026 Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection Trial Milestone Phase 2
March 4, 2026 8-K filed: Leadership change Corporate —
March 2, 2026 8-K filed: Other event Filing —
February 26, 2026 8-K filed: Material agreement Corporate —
February 23, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 Quarterly results filed (8-K) Earnings —
December 16, 2025 8-K filed: Material agreement, Other event Corporate —
December 9, 2025 Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Trial Milestone Phase 1
November 5, 2025 Quarterly results filed (8-K) Earnings —
August 6, 2025 Quarterly results filed (8-K) Earnings —
July 24, 2025 8-K filed: Other event Filing —
May 9, 2025 8-K filed: Other event Filing —
May 7, 2025 Quarterly results filed (8-K) Earnings —
March 1, 2025 A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 Trial Milestone Phase 1
October 15, 2024 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection Trial Milestone Phase 1/Phase 2
March 25, 2024 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection Trial Milestone Phase 2
May 5, 2023 A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Trial Milestone Phase 2
April 5, 2023 Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) Trial Milestone Phase 1
December 5, 2022 VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers Trial Milestone Phase 1
October 24, 2022 Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection Trial Milestone Phase 1
July 19, 2022 Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.